{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:01:44Z","timestamp":1705363304481},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[1985,1,1]],"date-time":"1985-01-01T00:00:00Z","timestamp":473385600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[1985]]},"DOI":"10.1007\/bf00543715","type":"journal-article","created":{"date-parts":[[2004,11,19]],"date-time":"2004-11-19T03:09:50Z","timestamp":1100833790000},"page":"77-84","source":"Crossref","is-referenced-by-count":16,"title":["Polymorphic metabolism of the ?-adrenoreceptor blocking drugs and its clinical relevance"],"prefix":"10.1007","volume":"28","author":[{"given":"R. L.","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0024-3205(74)90452-4","volume":"14","author":"B Ablad","year":"1974","unstructured":"Ablad B, Borg KO, Johnsson G, Rejardh CG, Solvell L (1974) Combined pharmacokinetics and pharmacodynamic studies on alprenolol and 4-hydroxy-alprenolol in man. Life Sci 14: 693?704","journal-title":"Life Sci"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(82)91583-5","volume":"1","author":"G Alvan","year":"1982","unstructured":"Alvan G, von Bahr C, Seideman P, Sjoqvist F (1982) High plasma concentrations of ?-receptor blocking drugs and deficient debrisoquine hydroxylation. Lancet 1: 333","journal-title":"Lancet"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1476-5381.1968.tb07949.x","volume":"34","author":"AM Barrett","year":"1968","unstructured":"Barrett AM, Cullum VA (1968) The biological properties of the optical isomers of propranolol and their effects upon cardiac arrhythmias. Br J Pharmacol 34: 43?55","journal-title":"Br J Pharmacol"},{"issue":"Suppl 2","key":"CR4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2165\/00003495-198300252-00082","volume":"25","author":"TA Betts","year":"1983","unstructured":"Betts TA, Alford C (1983) Beta-blocking drugs and sleep. A controlled trial. Drugs 25 [Suppl 2]: 268?272","journal-title":"Drugs"},{"key":"CR5","first-page":"602P","volume":"14","author":"AR Boobis","year":"1982","unstructured":"Boobis AR, Kahn GC, Murray S, Brodie MJ, Davies DS (1982) Evidence for a common defect in the impaired oxidation of substrates in the debrisoquine oxidation polymorphism. Br J Clin Pharmacol 14: 602P-603P","journal-title":"Br J Clin Pharmacol"},{"key":"CR6","first-page":"218P","volume":"16","author":"AR Boobis","year":"1983","unstructured":"Boobis AR, Hampden C, Murray S, Davies DS (1983) Reciprocal inhibition of debrisoquine and bufuralol oxidation in man. Br J Clin Pharmacol 16: 218P-219P","journal-title":"Br J Clin Pharmacol"},{"key":"CR7","first-page":"77","volume-title":"Progress in Drug Metabolism, vol. 6","author":"GR Bourne","year":"1981","unstructured":"Bourne GR (1981) The metabolism of ?-adrenoceptor blocking drugs. In: Bridges JW, Chasseaud L (eds) Progress in Drug Metabolism, vol. 6. Wiley, London, pp 77?110"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1476-5381.1982.tb09275.x","volume":"77","author":"RT Brittain","year":"1982","unstructured":"Brittain RT, Drew GM, Levy GP (1982) The ?- and ??-adrenoceptor blocking potencies of labetalol and its individual stereoisomers in anaesthetized dogs and in isolated tissues. Br J Pharmacol 77: 105?114","journal-title":"Br J Pharmacol"},{"key":"CR9","first-page":"1031","volume":"36","author":"FJ DiCarlo","year":"1977","unstructured":"DiCarlo FJ, Davidson IWF, Szpiech JM, Greenough RC, Leinweber FJ (1977) Bunolol: comparative metabolism in man, dog and rat as reflected by urinary components. Fed Proc 36: 1031","journal-title":"Fed Proc"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/cpt1979254416","volume":"25","author":"P Collste","year":"1979","unstructured":"Collste P, Borg KO, Astrom H, von Bahr C (1979) Contribution of 4-hydroxy-alprenolol to adrenergic beta receptor blockade of alprenolol. Clin Pharmacol Ther 25: 416?422","journal-title":"Clin Pharmacol Ther"},{"key":"CR11","first-page":"1650","volume":"286","author":"R Cove-Smith","year":"1983","unstructured":"Cove-Smith R, Kirk CA (1983) New drugs: beta blockers and sympathomimetics. Br Med J 286: 1650?1651","journal-title":"Br Med J"},{"key":"CR12","unstructured":"Dayer P, Balant L, K\u00fcpfer A, Fabre J (1983) Oxidation polymorphism and beta-blockers disposition: pharmacokinetics and therapeutic outcome. Proceedings of the Second World Conference on Clinical Pharmacology and Therapeutics, Washington DC, pp 39"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1365-2125.1982.tb01453.x","volume":"13","author":"P Dayer","year":"1982","unstructured":"Dayer P, Kuble A, K\u00fcpfer A, Courvoisier F, Balant L, Fabre J (1982) Defective hydroxylation of bufuralol associated with side effects of the drug in poor metabolisers. Br J Clin Pharmacol 13: 750?752","journal-title":"Br J Clin Pharmacol"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"472","DOI":"10.7326\/0003-4819-94-4-472","volume":"94","author":"J Feely","year":"1981","unstructured":"Feely J, Stevenson IH, Crooks J (1981a) Increased clearance of propranolol in thyrotoxicosis. Ann Intern Med 94: 472?474","journal-title":"Ann Intern Med"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJM198103193041202","volume":"304","author":"J Feely","year":"1981","unstructured":"Feely J, Wilkinson GR, Wood AJ (1981b) Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med 304: 692?695","journal-title":"N Engl J Med"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF03189265","volume":"1","author":"RJ Francis","year":"1976","unstructured":"Francis RJ, Allen JG, East PB, Ruane RJ (1976) The metabolism of bufuralol: urinary metabolite profiles in rat, dog and man. Eur J Drug Metab Pharmacokinet 1: 113?124","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/0002-8703(79)90195-9","volume":"97","author":"W Frishman","year":"1979","unstructured":"Frishman W (1979) Clinical pharmacology of the new beta-adrenergic blocking drugs. Part I. Pharmacodynamic and pharmacokinetic properties. Am Heart J 97: 663?670","journal-title":"Am Heart J"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-8703(73)90139-7","volume":"86","author":"DJ Greenblatt","year":"1973","unstructured":"Greenblatt DJ, Koch Weser J (1973) Adverse reactions to propranolol in hospitalized medical patients: a report from the Boston Collaborative Drug Surveillance Program. Am Heart J 86: 47","journal-title":"Am Heart J"},{"key":"CR19","first-page":"615","volume":"14","author":"DJ Greenblatt","year":"1972","unstructured":"Greenblatt DJ, Shader RI (1972) On the psychopharmacology of beta-adrenergic blockade. Curr Ther Res 14: 615?625","journal-title":"Curr Ther Res"},{"key":"CR20","first-page":"18","volume":"24","author":"RJ Herman","year":"1982","unstructured":"Herman RJ, Nakamura K, Wilkinson GR, Wood AJJ (1982) Induction of propranolol metabolism in man by rifampicin. Pharmacologist 24: 18","journal-title":"Pharmacologist"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0378-4347(00)80361-8","volume":"227","author":"J Hermansson","year":"1982","unstructured":"Hermansson J, von Bahr C (1982) Determination of (R)- and (S)-alprenolol and (R)- and (S)-metoprolol as their diastereoisomeric derivatives in human plasma by reversed phase liquid chromatography. J Chromatograph 227: 113?127","journal-title":"J Chromatograph"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/00498257909038710","volume":"9","author":"KJ Hoffman","year":"1979","unstructured":"Hoffman KJ, Arfwidsson A, Borg KO, Skanberg I (1979) Identification of urinary and biliary metabolites of alprenolol in the rat. Xenobiotica 9: 93?106","journal-title":"Xenobiotica"},{"key":"CR23","unstructured":"Idle JR, Smith RL (1984) The debrisoquine hydroxylation gene: a gene of multiple consequences. In: Lemberger L, Reidenberg MM (eds) Proceedings of the Second World Congress of Clinical Pharmacology and Therapeutics, Washington DC, pp 148?164"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/cpt1976194416","volume":"19","author":"CM Kaye","year":"1976","unstructured":"Kaye CM, Kumana CR, Leighton M, Hamer J, Turner P (1976) Observations on the pharmacokinetics of acebutolol. Clin Pharmacol Ther 19: 416?420","journal-title":"Clin Pharmacol Ther"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1365-2125.1984.tb02403.x","volume":"17","author":"MS Lennard","year":"1984","unstructured":"Lennard MS, Jackson PR, Freestone S, Tucker GT, Ramsay LE, Woods HF (1984) The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol. Br J Clin Pharmacol 17: 679?685","journal-title":"Br J Clin Pharmacol"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1056\/NEJM198212163072505","volume":"307","author":"MS Lennard","year":"1982","unstructured":"Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF (1982) Oxidation phenotype ? a major determinant of metoprolol metabolism and response. N Engl J Med 307: 1558?1560","journal-title":"N Engl J Med"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/clpt.1983.242","volume":"34","author":"MS Lennard","year":"1983","unstructured":"Lennard MS, Tucker GT, Silas JH, Freestone S, Ramsay LE, Woods HF (1983) Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquine metabolizers. Clin Pharmacol Ther 34: 732?737","journal-title":"Clin Pharmacol Ther"},{"key":"CR28","unstructured":"Lewis RV, Lennard MS, Jackson PR, Tucker GT, Ramsay LE, Woods HF (1984) Timolol, atenolol and oxidation phenotype. Br J Clin Pharmacol 18: 287P"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0140-6736(77)91430-1","volume":"2","author":"A Mahgoub","year":"1977","unstructured":"Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2: 584?586","journal-title":"Lancet"},{"key":"CR30","first-page":"351","volume":"7","author":"WL Nelson","year":"1979","unstructured":"Nelson WL, Powell ML (1979) Evidence for an area oxide-NIH shift in the metabolic conversion of propranolol to 4?-hydroxy-propranolol. Drug Metab Dispos 7: 351?355","journal-title":"Drug Metab Dispos"},{"key":"CR31","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM198104023041401","volume":"304","author":"Norwegian Multicentre Study Group","year":"1981","unstructured":"Norwegian Multicentre Study Group (1981) Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304: 801?807","journal-title":"N Engl J Med"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/clpt.1984.138","volume":"36","author":"TC Raghuram","year":"1984","unstructured":"Raghuram TC, Koshakji RP, Wilkinson GR, Wood AJJ (1984) ?Polymorphic ability to metabolise propranolol alters 4-hydroxypropranolol levels but not beta blockade?. Clin Pharmacol Ther 36: 51?56","journal-title":"Clin Pharmacol Ther"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3109\/00498257409052112","volume":"4","author":"W Riess","year":"1974","unstructured":"Riess W, Huerzeler H, Raschdorf F (1974) The metabolites of oxprenolol (Trasicor) in man. Xenobiotica 4: 365?373","journal-title":"Xenobiotica"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1111\/j.1365-2125.1984.tb02423.x","volume":"17","author":"JH Silas","year":"1984","unstructured":"Silas JH, Lennard MS, Tucker GT, Ramsay LE, Woods HF (1984) Polymorphic metabolism of ?-adrenoceptor antagonists. Br J Clin Pharmacol 17: 11S-18S","journal-title":"Br J Clin Pharmacol"},{"key":"CR35","first-page":"349","volume-title":"Genetic polymorphisms of drug oxidation in man","author":"RL Smith","year":"1985","unstructured":"Smith RL (1985) Genetic polymorphisms of drug oxidation in man. Proceedings of the 6th International Symposium on Microsomes and Drug Oxidation, Brighton, England. Taylor and Francis, London, pp 349?360"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/cpt1979262153","volume":"26","author":"EA Sotaniemi","year":"1979","unstructured":"Sotaniemi EA, Antilla M, Pelkonen RO, Jarvensivu P, Sudquist H (1979) Plasma clearance of propranolol and sotalol and hepatic drug-metabolizing enzyme activity. Clin Pharmacol Ther 26: 153?161","journal-title":"Clin Pharmacol Ther"},{"key":"CR37","unstructured":"Trager W, Testa B (1984) Stereochemical considerations. In: Caldwell J, Paulson G (eds) Foreign Compound Metabolism. Proceedings of International Society for the Study of Xenobiotics Symposium, Florida 1983, pp 91?99"},{"key":"CR38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/cpt19792618","volume":"26","author":"RE Vestal","year":"1979","unstructured":"Vestal RE, Wood AJJ, Branch RA, Shand DG, Wilkinson GR (1979) The effects of age and cigarette smoking on propranolol disposition. Clin Pharmacol Ther 26: 8?15","journal-title":"Clin Pharmacol Ther"},{"key":"CR39","doi-asserted-by":"crossref","first-page":"603P","DOI":"10.1111\/j.1365-2125.1982.tb04937.x","volume":"14","author":"C Bahr von","year":"1982","unstructured":"von Bahr C, Birgersson C, Bertilsson L, Goransson M, Mellstrom B, Nilsell K, Sjoqvist F (1982) Drug metabolism in human liver microsomes; towards marker substrates for different enzymes. Br J Clin Pharmacol 14: 603P-604P","journal-title":"Br J Clin Pharmacol"},{"key":"CR40","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1365-2125.1984.tb02537.x","volume":"18","author":"T Walle","year":"1984","unstructured":"Walle T, Walle UK, Wilson MJ, Fagan TC, Gaffney TE (1984) Stereoselective ring oxidation of propranolol in man. Br J Clin Pharmacol 18: 741?747","journal-title":"Br J Clin Pharmacol"},{"key":"CR41","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/clpt.1983.81","volume":"33","author":"PG Wells","year":"1983","unstructured":"Wells PG, Feely J, Wilkinson GR, Wood AJJ (1983) Effects of thyrotoxicosis on liver blood flow and the disposition of propranolol after chronic dosing. Clin Pharmacol Ther 33: 603?608","journal-title":"Clin Pharmacol Ther"},{"key":"CR42","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM198211183072116","volume":"307","author":"A Westerlund","year":"1982","unstructured":"Westerlund A (1982) Letter to editor. N Engl J Med 307: 1343?1344","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"CR43","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2165\/00003495-198300252-00087","volume":"25","author":"A Westerlund","year":"1983","unstructured":"Westerlund A (1983) A comparison of the central nervous system side effects caused by lipophilic and hydrophilic beta-blockers. Drugs 25 [Suppl 2]: 280?281","journal-title":"Drugs"},{"key":"CR44","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/03602537208993910","volume":"1","author":"KW Wong","year":"1972","unstructured":"Wong KW, Schreiber EC (1972) Recent developments in beta adrenergic blocking drugs. Drug Metab Rev 1: 101?116","journal-title":"Drug Metab Rev"},{"key":"CR45","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2165\/00003088-197803060-00005","volume":"3","author":"AJJ Wood","year":"1978","unstructured":"Wood AJJ, Kornhauser DM, Wilkinson GR, Shand DG, Branch RA (1978) The influence of cirrhosis on steady state blood concentration of unbound propranolol after oral administration. Clin Pharmacokinet 3: 478?487","journal-title":"Clin Pharmacokinet"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00543715.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00543715\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00543715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T15:26:50Z","timestamp":1705332410000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00543715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985]]},"references-count":45,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[1985]]}},"alternative-id":["BF00543715"],"URL":"https:\/\/doi.org\/10.1007\/bf00543715","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[1985]]}}}